Benzinga

Benzinga

Benzinga

samedi, septembre 05

Charles River Laboratories International Inc

CRLNYSE
Trade with Public
Trade with Public
$288.50
-4.85-1.65%
À la clôture: Sep 4, 5:00 PM EST
$288.50
N/A
Après les heures: 4:15 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Charles River Financials

Charles River (CRL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
Avi Kapoor

Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High

Charles River (CRL) stock jumped after Q2 earnings beat estimates and the company raised its full-year 2026 guidance.
Vandana Singh

PRO
Charles River Lowers FY2026 GAAP EPS Guidance from $5.35-$5.85 to $3.05-$3.35 vs $6.24 Est

Charles River (NYSE:CRL) lowers FY2026 GAAP EPS guidance from $5.35-$5.85 to $3.05-$3.35 vs $6.24 analyst estimate..
Benzinga Newsdesk

PRO
Charles River Raises FY2026 Adj EPS Guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 Est; Raises FY2026 Sales Guidance from $3.794B-$3.854B to $3.879B-$3.920B vs $3.850B Est

Charles River (NYSE:CRL) raises FY2026 Adj EPS guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 analyst estimate. Raises FY2026 sales outlook from $3.794 billion-$3.854 billion to $3.879 billion-$3.920 billion vs
Benzinga Newsdesk

PRO
Charles River Q2 Adj. EPS $3.02 Beats $2.74 Estimate, Sales $1.004B Beat $975.687M Estimate

Charles River (NYSE:CRL) reported quarterly earnings of $3.02 per share which beat the analyst consensus estimate of $2.74 by 10.22 percent. This is a 3.21 percent decrease over earnings of $3.12 per share from the same
Benzinga Newsdesk

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.
Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved